Target intelligence / Profile preview

Filaggrin (FLG) (FLG)

Target
FLG
Molecular classification
Other (keratin-binding protein, structural protein of the epidermis)
01

Overview

Filaggrin is a structural protein vital for epidermal barrier function in human skin. Synthesized as the precursor profilaggrin, it is stored in keratohyalin granules in the upper epidermis. During terminal differentiation, profilaggrin is dephosphorylated and cleaved to release monomeric filaggrin, which aggregates keratin intermediate filaments, leading to flattened, hardened skin cells that form an effective barrier. Degradation of filaggrin contributes to production of the "natural moisturizing factor" (NMF), crucial for skin hydration and pH maintenance. Loss-of-function mutations in the FLG gene are a principal genetic cause for ichthyosis vulgaris and a major predisposing factor for atopic dermatitis (eczema), as well as increased risk of asthma and possibly other allergic conditions. There is currently no approved pharmacological modulator of filaggrin; research and clinical efforts focus on barrier repair strategies and genetic counseling in at-risk individuals.

Other names
ProfilaggrinFLG
02

Mechanism of action

Not applicable; no direct approved modulators of filaggrin. Experimental approaches include barrier repair creams, emollients, or agents used to increase skin hydration or mimic natural moisturizing factor.

03

Biological functions

Skin barrier formationKeratin aggregationMaintenance of epidermal hydration (formation of natural moisturizing factor)Regulation of skin pH
04

Disease associations

Atopic dermatitis (eczema)Ichthyosis vulgarisAsthma (predisposition in FLG mutation carriers)Increased skin infection susceptibility (through impaired barrier)Other (increased susceptibility to allergic diseases)
05

Safety considerations

None inherent to filaggrin as a therapeutic target because it is not typically acted upon directly by drugs.Challenges are primarily with genetic therapies or systemic approaches, given filaggrin’s structural role and complexity of topical or gene-based interventions.
06

Biomarkers

FLG gene mutation status (R501X, 2284del4, S2554X, 3321delA, etc.) for risk of atopic dermatitis, ichthyosis vulgaris, and atopic diseasePresence of filaggrin protein in skin biopsies as an indicator of barrier integrity

Beyond the preview

Go deeper on Filaggrin (FLG) (FLG).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Filaggrin (FLG) (FLG).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call